GSK Collaborate with CureVac to Develop Next Generation mRNA COVID-19 Vaccines
Shots:
- CureVac to receive $90.14M up front- $90.14M as milestones on the achievement of specific milestones. GSK will be the marketing authorization holder for the vaccine (Ex-Switzerland) and will have exclusive rights in all countries except Germany- Austria and Switzerland
- Additionally- GSK will support the manufacture of ~100M doses of CureVac’s first generation COVID-19 vaccine candidate CVnCoV in 2021
- The development program will begin imminently- with the target of introducing the vaccine in 2022- subject to regulatory approval
Ref: GSK | Image: GSK
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com